NDATOPICALCREAM
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RHOFADE is a topical cream formulation of oxymetazoline hydrochloride, a selective alpha-1 adrenergic agonist approved in January 2017. The drug is indicated for persistent facial erythema (rosacea) and works by constricting blood vessels to reduce redness and flushing. It represents a mechanistic advance in dermatology by offering targeted vasoconstriction at the skin surface.
$3.0MPart D
PeakStable
9.0 years to LOEProduct is in peak commercial phase with modest Part D utilization; team size and hiring likely focused on sustaining current market position rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Started Apr 2019
1,105 enrolled
Rosacea
Career Relevance
RHOFADE offers a stable, niche commercial opportunity in dermatology with minimal competitive pressure and a well-differentiated mechanism in rosacea treatment. Career roles are concentrated in commercial execution, field engagement, and medical affairs rather than clinical development, making this suitable for professionals focused on product marketing, sales, and physician relationships in specialty dermatology.
Brand Manager
Worked on RHOFADE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.